Patents by Inventor Christine Labeur

Christine Labeur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180362617
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 20, 2018
    Applicant: Ablynx N.V.
    Inventors: ANN BRIGE, Christine Labeur, Marc Jozef Lauwereys
  • Patent number: 10005830
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: June 26, 2018
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Patent number: 9884117
    Abstract: Stable formulations are provided that contain immunoglobulin single variable domains at a high concentration. The formulations are useful as pharmaceutical formulation and suitable for subcutaneous administration. The formulations can be transported and stored under various stress conditions. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Publication number: 20170081692
    Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Applicant: Ablynx N.V.
    Inventors: PETER SCHOTTE, Patrick Stanssens, Christine Labeur, Jean-Luc Jonniaux, Marc Jozef Lauwereys
  • Patent number: 9464138
    Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: October 11, 2016
    Assignee: Ablynx N.V.
    Inventors: Peter Schotte, Patrick Stanssens, Christine Labeur, Jean-Luc Jonniaux, Marc Jozef Lauwereys
  • Publication number: 20160279242
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 29, 2016
    Applicant: Ablynx N.V.
    Inventors: ANN BRIGE, Christine Labeur, Veronique De Brabandere, Marc Jozef Lauwereys
  • Patent number: 9265834
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: February 23, 2016
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Veronique De Brabandere, Marc Lauwereys
  • Publication number: 20140178383
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from Tween 80, Tween 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Application
    Filed: August 12, 2013
    Publication date: June 26, 2014
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Veronique De Brabandere, Marc Lauwereys
  • Publication number: 20130012916
    Abstract: The present invention relates to formulations and methods for administering therapeutic molecules comprising immunoglobulin variable domains using needle-free delivery devices.
    Type: Application
    Filed: February 10, 2011
    Publication date: January 10, 2013
    Applicants: Glide Pharmaceutical Technologies Limited, Ablynx N.V.
    Inventors: Christine Labeur, Hilde Adi Pierrette Revets, Nasir Hussain, Charles Potter
  • Patent number: 8343932
    Abstract: The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: January 1, 2013
    Assignee: Pronota N.V.
    Inventors: Sven Eyckerman, Koen Kas, Christine Labeur
  • Publication number: 20120201812
    Abstract: Stable formulations are provided that contain immunoglobulin single variable domains at a high concentration. The formulations are useful as pharmaceutical formulation and suitable for subcutaneous administration. The formulations can be transported and stored under various stress conditions. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Application
    Filed: September 3, 2010
    Publication date: August 9, 2012
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Publication number: 20120157664
    Abstract: The present disclosure relates to a method for producing a domain antibody in a host other than E. coli, preferably yeast, comprising a) applying conditions that promote the formation of disulfide bridges in domain antibodies, or b) removing domain antibodies lacking at least one disulfide bridge, or c) a combination of (a) and (b).
    Type: Application
    Filed: April 30, 2010
    Publication date: June 21, 2012
    Applicant: Ablynx N.V.
    Inventors: Peter Schotte, Patrick Stanssens, Christine Labeur, Jean-Luc Jonniaux, Marc Jozef Lauwereys
  • Publication number: 20120093839
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: March 2, 2010
    Publication date: April 19, 2012
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Publication number: 20110091462
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: March 5, 2009
    Publication date: April 21, 2011
    Applicant: ABLYNX N.V.
    Inventors: Peter Casteels, Marc Jozef Lauwereys, Patrick Stanssens, Christine Labeur, Carlo Boutton, Ann Brigé, Hendricus Renerus Jacobus M Hoogenboom, Els Anna Alice Beirnaert
  • Publication number: 20100222276
    Abstract: The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 2, 2010
    Applicant: Pronota N.V.
    Inventors: Sven Eyckerman, Koen Kas, Christine Labeur
  • Patent number: 5733879
    Abstract: The subject invention relates to amino acid sequences derived from peptide (Glu.sup.1,8, Leu.sup.11,17) 18A, comprising:Glu-Trp-Leu-A-Ala-B-Tyr-C-Lys-Val-D-Glu-Lys-Leu-Lys-Glu-Leu-Phe,wherein A is Lys, Glu or Asp; B is Phe, Glu or Asp; C is Glu, Lys or Arg;and D is Leu, Glu or Asp. The amino acid sequences form complexes with phospholipids, and are useful for the treatment of cardiovascular disease.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: March 31, 1998
    Assignee: N.V. Innogenetics, S.A.
    Inventors: Maryvonne Rosseneu, Robert Brasseur, Robert Deleys, Christine Labeur